What is the difference between NOACs and Aspirin in AF patients?
The Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial compared apixaban 5 mg bid with aspirin in AF patients who were not candidates for VKA. The trial was stopped early for benefit as apixaban significantly reduced the risk of stroke or systemic embolism compared with aspirin (HR, 0.45; 95% CI, 0.32-0.62; P < .001). There was no significant difference in major bleeding (HR, 1.13; 95% CI, 0.74-1.75; P .57) between apixaban and aspirin.